Synergistic effect of tamoxifen and ruxolitinib combination in reducing disease burden in myeloproliferative neoplasms (2025)
- Authors:
- Pereira-Martins, Diego Antonio
- Alves-Silva, Antonio Bruno
- Melo, Manuela Albuquerque de
- Fonseca, Natasha Peixoto
- Weinhäuser, Isabel
- Perez, Fabio Augusto Bueno
- Bellomi, Artur Bernardo Ribeiro
- Figueiredo-Pontes, Lorena Lobo
- Quek,Lynn
- Chatzikyriakou, Prodomos
- Huls, Gerwin A.
- Ammatuna, Emanuele
- Schuringa, Jan Jacob
- Traina, Fabiola
- Machado Neto, João Agostinho
- Pereira-Martins, Diego Antonio
- USP affiliated authors: PONTES, LORENA LÔBO DE FIGUEIREDO - FMRP ; TRAINA, FABÍOLA - FMRP ; MACHADO NETO, JOÃO AGOSTINHO - ICB ; SILVA, ANTONIO BRUNO ALVES DA - FMRP ; MELO, MANUELA ALBUQUERQUE DE - FMRP ; FONSECA, NATASHA PEIXOTO - FMRP ; PEREZ, FÁBIO AUGUSTO BUENO - FMRP ; BELLOMI, ARTUR BERNARDO RIBEIRO - FMRP
- Unidades: FMRP; ICB
- DOI: 10.1182/blood-2024-209823
- Subjects: FARMACOLOGIA; DOENÇAS SANGUÍNEAS E LINFÁTICAS; MEDULA ÓSSEA; CÉLULAS SANGUÍNEAS; MUTAÇÃO GENÉTICA; CITOMETRIA DE FLUXO; CAMUNDONGOS; CÉLULAS MIELOIDES; LEUCEMIA MIELOIDE; NEOPLASIAS POR TIPO HISTOLÓGICO
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: Wahington, DC
- Date published: 2025
- Source:
- Conference titles: The 66th ASH Annual Meeting Abstracts
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
PEREIRA-MARTINS, Diego Antonio et al. Synergistic effect of tamoxifen and ruxolitinib combination in reducing disease burden in myeloproliferative neoplasms. Blood, v. 144, p. 4518-4519, 2025Tradução . . Disponível em: https://doi.org/10.1182/blood-2024-209823. Acesso em: 15 fev. 2026. -
APA
Pereira-Martins, D. A., Alves-Silva, A. B., Melo, M. A. de, Fonseca, N. P., Weinhäuser, I., Perez, F. A. B., et al. (2025). Synergistic effect of tamoxifen and ruxolitinib combination in reducing disease burden in myeloproliferative neoplasms. Blood, 144, 4518-4519. doi:10.1182/blood-2024-209823 -
NLM
Pereira-Martins DA, Alves-Silva AB, Melo MA de, Fonseca NP, Weinhäuser I, Perez FAB, Bellomi ABR, Figueiredo-Pontes LL, Quek L, Chatzikyriakou P, Huls GA, Ammatuna E, Schuringa JJ, Traina F, Machado Neto JA. Synergistic effect of tamoxifen and ruxolitinib combination in reducing disease burden in myeloproliferative neoplasms [Internet]. Blood. 2025 ; 144 4518-4519.[citado 2026 fev. 15 ] Available from: https://doi.org/10.1182/blood-2024-209823 -
Vancouver
Pereira-Martins DA, Alves-Silva AB, Melo MA de, Fonseca NP, Weinhäuser I, Perez FAB, Bellomi ABR, Figueiredo-Pontes LL, Quek L, Chatzikyriakou P, Huls GA, Ammatuna E, Schuringa JJ, Traina F, Machado Neto JA. Synergistic effect of tamoxifen and ruxolitinib combination in reducing disease burden in myeloproliferative neoplasms [Internet]. Blood. 2025 ; 144 4518-4519.[citado 2026 fev. 15 ] Available from: https://doi.org/10.1182/blood-2024-209823 - Autophagy and inflammasome activation are associated with poor response to FLT3 inhibitors in patients with FLT3-ITD acute myeloid leukemia
- Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells
- Irs1S57X heterozygous mutant mice display normal hematopoiesis and phenotypic features, while homozygous knockout exhibit high fetal or postnatal lethality
- Metformin inhibits STAT3 and MAPK signaling through AMPK activation in CSF3RT618I cells
- Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model
- De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes
- Stathmin 1 expression in plasma cell neoplasms. [Carta]
- Increased levels of cyclin D1 negatively impacts on acute lymphoblastic leukemia overall survival
- DNMT3A is highly expressed in bone marrow cells from acute myeloid leukemia patients
- Effects of RhoA and RhoC upon the sensitivity of prostate cancer cells to glutamine deprivation
Informações sobre o DOI: 10.1182/blood-2024-209823 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
